Robust product sales by AstraZeneca in Q3, as it turns the corner and gets ready for the growth phase. The new drugs and the Emerging Markets (EMs), particularly China, came out as the highlights of the quarter. Profitability continued to decline but this is already discounted and the company should start working on the cost side from 2019. A big disappointment, however, was the failure of Imfinzi in the MYSTIC trial, yet again.
19 Nov 2018
Solid Q3 followed by another MYSTIC failure
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid Q3 followed by another MYSTIC failure
AstraZeneca PLC (AZN:LON) | 11,253 225.1 0.0% | Mkt Cap: 174,447m
- Published:
19 Nov 2018 -
Author:
Kamla Singh -
Pages:
4
Robust product sales by AstraZeneca in Q3, as it turns the corner and gets ready for the growth phase. The new drugs and the Emerging Markets (EMs), particularly China, came out as the highlights of the quarter. Profitability continued to decline but this is already discounted and the company should start working on the cost side from 2019. A big disappointment, however, was the failure of Imfinzi in the MYSTIC trial, yet again.